Patents Assigned to Gilead Sciences, Inc.
  • Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections
    Patent number: 10501476
    Abstract: Provided herein are formulations, methods and substituted thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidine compounds.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: December 10, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael O'Neil Hanrahan Clarke, Richard L. Mackman, Dustin Siegel
  • Methods of treating liver fibrosis
    Patent number: 10495648
    Abstract: The present application provides methods of diagnosing, treating, and/or monitoring a liver disease or condition in a human.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: December 3, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Nandita Amartya Kumar Sarkar, Ren Y. Xu, Biao Li
  • FXR (NR1H4) binding and activity modulating compounds
    Patent number: 10485795
    Abstract: The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 26, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Olaf Kinzel, Christoph Steeneck, Claus Kremoser
  • Phosphatidylinositol 3-kinase inhibitors
    Patent number: 10479770
    Abstract: The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, R1, R2, R3, R4, and R6 are as described herein.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: November 19, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jayaraman Chandrasekhar, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Nicholas Alexander Till, Jennifer Anne Treiberg, William J. Watkins, Julian A. Codelli, Joshua J. Van Veldhuizen
  • Macrocyclic inhibitors of flaviviridae viruses
    Patent number: 10472392
    Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: November 12, 2019
    Assignees: Gilead Sciences, Inc., Cypralis Limited
    Inventors: Caroline Aciro, Jean Yves Chiva, David Kenneth Dean, Adrian John Highton, Petr Jansa, Andrew John Keats, Linos Lazarides, Richard Mackman, Karine G. Poullennec, Adam James Schrier, Dustin Scott Siegel, Victoria Alexandra Steadman, Greg Watt
  • Substituted dipyrido[1,2-a:1?,2?-d]pyrazines for treating viral infections
    Patent number: 10456395
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein L, R1, R5, W, X, Y1, Y2, and Z are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: October 29, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Hyung-Jung Pyun, Manoj C. Desai, Haolun Jin, Mingzhe Ji, Teresa Alejandra Trejo Martin
  • Compounds for the treatment of hepatitis B virus infection
    Patent number: 10442804
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: October 15, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Evangelos Aktoudianakis, Eda Canales, Kevin S. Currie, Darryl Kato, Jiayao Li, John O. Link, Samuel E. Metobo, Roland D. Saito, Scott D. Schroeder, Nathan Shapiro, Winston C. Tse, Qiaoyin Wu, Yunfeng Eric Hu
  • ANTIBODIES AND FRAGMENTS THEREOF THAT BIND HEPATITIS B VIRUS PROTEIN X
    Publication number: 20190309052
    Abstract: Provided herein are, inter alia, antibodies, antigen-binding antibody fragments, cells, polynucleotides, compositions, kits, and methods relating to the detection of HBV protein X (HBx), e.g., in vitro and in vivo. Included are antibodies and fragments thereof that bind HBx, as well as kits, cells, and compositions comprising such antibodies and fragments.
    Type: Application
    Filed: April 1, 2019
    Publication date: October 10, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Simon Paul Fletcher, Christian Alfons Voitenleitner
  • FXR (NR1H4) Modulating Compounds
    Publication number: 20190308962
    Abstract: The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 10, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • FXR (NR1H4) modulating compounds
    Patent number: 10421730
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 24, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Process methods for phosphatidylinositol 3-kinase inhibitors
    Patent number: 10414737
    Abstract: A process for the synthesis of quinazolinone containing compounds which may be useful for the treatment of cancer, is hereby disclosed. In addition, compound intermediates relating to these processes are also disclosed.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 17, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Stacy Bremner, Jerry B. Evarts, Keiko Sujino, Duong Tran, Dragos Vizitiu
  • Crystalline forms of darunavir
    Patent number: 10407438
    Abstract: The present invention relates to novel crystalline forms of darunavir, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Chiajen Lai, Bing Shi
  • Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate
    Patent number: 10385067
    Abstract: The present invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1?,2?:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate Form I, pharmaceutical formulations, and uses thereof for treating or prophylactically preventing an HIV infection.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: August 20, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Ernest A. Carra, Irene Chen, Vahid Zia
  • COT MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20190248807
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Application
    Filed: April 23, 2019
    Publication date: August 15, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chienhung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary B. Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections
    Patent number: 10377761
    Abstract: Provided herein are formulations, methods and substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: August 13, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael O'Neil Hanrahan Clarke, Edward Doerffler, Richard L. Mackman, Dustin Siegel
  • Compounds for the treatment of HIV
    Patent number: 10370358
    Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: August 6, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Steven S. Bondy, Carina E. Cannizzaro, Chien-Hung Chou, Randall L. Halcomb, Yunfeng Eric Hu, John O. Link, Qi Liu, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Toll like receptor modulator compounds
    Patent number: 10370342
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: August 6, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Inhibitors of bruton'S tyrosine kinase
    Patent number: 10370381
    Abstract: Provided are forms of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, compositions thereof, methods for their preparation, and methods for their use.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 6, 2019
    Assignee: Gilead Sciences, Inc.
    Inventor: Bing Shi
  • HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES
    Publication number: 20190211083
    Abstract: The present invention provides novel anti-HIV antibodies with improved therapeutic properties, related pharmaceutical compositions, and methods of use thereof.
    Type: Application
    Filed: February 12, 2019
    Publication date: July 11, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Mini Balakrishnan, Brian A. Carr, John Corbin, Craig S. Pace, Nathan D. Thomsen, Xue Zhang
  • HIV PROTEASE INHIBITORS
    Publication number: 20190210978
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herin. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Application
    Filed: October 12, 2018
    Publication date: July 11, 2019
    Applicant: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Aesop Cho, Ana Zurisadai Gonzalez Buenrostro, Xiaochun Han, Salman Y. Jabri, Ryan McFadden, Yingmei Qi, Johannes Voigt, Hong Yang, Jie Xu, Lianhong Xu